Table 4.
Canonical pathways in NextBio that were significantly enriched following ASD gene-targeted shRNA constructs, but not affected by luciferase shRNA
| |
ASD gene count |
Fmr1 |
Mecp2 |
Mef2a |
Mef2d |
Nlgn1 |
Nlgn3 |
Pten |
Shank3 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogroup | Up | Down | Up | Down | Up | Down | Up | down | Up | Down | Up | Down | Up | Down | Up | Down | |
| TrkA receptor |
8 |
|
2 |
|
4 |
|
2 |
|
2 |
|
2 |
|
3 |
3 |
|
|
2 |
| Erythropoietin-mediated neuroprotection through NFKB |
7 |
3 |
2 |
|
3 |
|
3 |
|
1 |
|
2 |
|
1 |
3 |
|
|
|
| PGC1A pathway |
7 |
|
|
|
8 |
|
5 |
|
7 |
|
3 |
|
4 |
|
9 |
|
4 |
| Long-term potentiation |
7 |
8 |
|
|
18 |
|
5 |
|
15 |
3 |
|
|
|
|
16 |
|
6 |
| Cell adhesion molecules (CAMs) |
7 |
|
|
10 |
14 |
|
8 |
|
13 |
|
8 |
|
11 |
13 |
12 |
|
10 |
| G2 and M phases |
7 |
|
1 |
|
1 |
|
1 |
1 |
1 |
|
1 |
|
2 |
3 |
|
|
|
| P53 HYPOXIA pathway |
7 |
|
3 |
|
3 |
|
3 |
|
3 |
|
2 |
|
3 |
6 |
|
|
|
| Biosynthesis of steroids |
6 |
|
8 |
|
5 |
|
|
|
3 |
2 |
|
|
5 |
|
4 |
|
|
| Arginine and proline metabolism |
6 |
|
8 |
|
9 |
1 |
|
|
8 |
|
|
|
8 |
5 |
|
|
|
| Antigen processing and presentation |
6 |
|
|
|
9 |
|
3 |
|
6 |
|
3 |
|
10 |
|
|
|
4 |
| BAD pathway |
6 |
|
3 |
|
|
|
3 |
|
4 |
2 |
|
2 |
|
|
|
|
2 |
| Neuroregulin receptor degredation protein-1 controls ERBB3 receptor recycling |
6 |
|
|
1 |
|
1 |
|
1 |
|
1 |
|
1 |
|
|
|
1 |
|
| Eicosanoid synthesis |
6 |
|
|
|
|
|
1 |
|
1 |
|
1 |
|
1 |
3 |
|
|
2 |
| Phosphatidylinositol signaling system |
5 |
10 |
|
|
17 |
|
|
|
|
|
6 |
|
11 |
|
10 |
|
|
| Vitamin B6 metabolism | 5 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | |||||||||